Indaptus Therapeutics (INDP) Receivables - Other (2021 - 2023)

Indaptus Therapeutics (INDP) posted quarterly Receivables - Other of $19062.0 for Q1 2023, down 9.47% quarter-over-quarter from $21056.0 in Q4 2021.

Indaptus Therapeutics (INDP) Receivables - Other (2021 - 2023) Analysis & Trends

Indaptus Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $19062.0 for Q1 2023.

In Q1 2023, Receivables - Other changed N/A year-over-year to $19062.0; the TTM figure through Mar 2023 stood at $19062.0 (changed N/A YoY), while the FY2021 annual figure was $21056.0, changed N/A from the prior year.
Receivables - Other for Q1 2023 stood at $19062.0, down from $21056.0 in the prior quarter.
The five-year high for Receivables - Other was $21056.0 in Q4 2021, with the low at $19062.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Indaptus Therapeutics	146.91 Mn	135.35 Mn	-

Download Data